Metastatic Castration-resistant Prostate Cancer (mCRPC) research hub
26 indexed studies · 9 currently recruiting
- recruitingPHASE3
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
This study compares a new medicine, opevesostat, with existing treatments like abiraterone or enzalutamide for prostate cancer that has spread and is no longer responding well to standard hormone therapy. It aims to see if opevesostat is safer and more effective at stopping cancer growth.
United States · Australia · Brazil - active not recruitingPHASE3
An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
This study is looking at a new combination of medicines for men with advanced prostate cancer that has stopped responding to standard hormone therapy. It aims to see if adding a drug called apalutamide to current treatment helps men live longer without their cancer getting worse.
United States · Argentina · Australia - active not recruitingPHASE3
A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
This study looks at a new drug, apalutamide, for men with prostate cancer that hasn't spread but is resistant to standard treatment. It aims to see if the drug can stop the cancer from spreading and if it's safe to use.
United States · Australia · Austria - recruitingPHASE3
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
This study is testing a new medicine, ifinatamab deruxtecan (I-DXd), for men with advanced prostate cancer that has spread and isn't responding to hormone therapy. We want to see if I-DXd helps men live longer and keeps their cancer from growing compared to standard chemotherapy.
United States · Argentina · Australia - active not recruitingPHASE3
An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
This study looks at a new drug, apalutamide, alongside standard radiation for high-risk prostate cancer. Researchers want to see if this combination improves how long patients live without the cancer spreading, compared to usual treatments.
United States · Argentina · Belgium - active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
This study looks at a new combination of drugs, pembrolizumab and enzalutamide, for men with advanced prostate cancer that has spread and no longer responds to hormone therapy. It compares this combination to enzalutamide alone to see if it helps men live longer and stops the cancer from growing.
United States · Argentina · Australia - active not recruitingPHASE3
A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)
This study looks at a new drug, abemaciclib, combined with standard treatment for prostate cancer that has spread. We want to see if this combination can stop the cancer from getting worse for longer in men whose cancer is still responding to hormone therapy.
United States · Argentina · Australia - active not recruiting
Imperial Prostate 6 - Cancer Histology Artificial Intelligence Reliability Study.
This study is looking at how well a new artificial intelligence (AI) system called Galen Prostate AI can help doctors diagnose prostate cancer from tissue samples. It aims to see if AI can make diagnoses faster and more consistent, especially with increasing numbers of biopsies.
United Kingdom - active not recruitingPHASE3
Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer
This study looks at a new way to treat prostate cancer that has spread. It compares a drug called enzalutamide with standard treatments to see which works best when started early. We want to find out if enzalutamide can help men newly diagnosed with advanced prostate cancer.
United States · Australia · Canada - active not recruitingPHASE1
A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer
This study is looking at a new prostate cancer drug, JNJ-56021927, alongside existing treatments like abiraterone acetate and prednisone. Researchers want to see if these drugs work well together, check for side effects, and find the best doses for future studies in men with advanced prostate cancer.
United States · Canada · Netherlands - recruitingNA
Imperial Prostate 7 - Prostate Assessment Using Comparative Interventions - Fast Mri and Image-fusion for Cancer
This study looks at new ways to find prostate cancer using MRI scans and biopsies. Researchers want to see if a shorter, simpler MRI is as good as the usual one, and if guiding biopsies with a computer is better than relying on a doctor’s eye.
United Kingdom - ongoing, recruitingHuman Pharmacology (Phase I)- Other
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
This study is looking at a new treatment combination for prostate cancer that has spread in men. It combines two medicines, abemaciclib and darolutamide, to see if they can help slow down or stop the cancer's growth after previous treatments haven't worked well enough.
Spain · Germany - recruitingPHASE1
A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer
This study is testing two new drugs, Pasritamig and JNJ-86974680, together for men with advanced prostate cancer. The main goal is to find the best and safest dose of these drugs when used in combination.
United States · United Kingdom - recruitingPHASE1
A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer
This study is looking at two new medicines, JNJ-78278343 and JNJ-95298177, to treat prostate cancer that has spread and is no longer responding to usual hormone treatments. We want to find the best dose and see how safe and effective this combination is.
United States · United Kingdom - active not recruitingPHASE3
177Lu-PSMA-617 vs. Androgen Receptor-Directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer
This study compares a new treatment, 177Lu-PSMA-617, with standard hormone therapy for advanced prostate cancer. It aims to see if the new treatment helps people live longer or keeps their cancer in check for longer, for those who haven't had certain chemotherapy.
United States · Austria · Belgium - active not recruitingPHASE3
Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localised, Prostate Cancer
This study looks at a medicine called enzalutamide for men with prostate cancer that hasn't spread but is high-risk. It aims to see if adding enzalutamide to standard hormone therapy and radiation helps prevent the cancer from coming back.
United States · Australia · Austria - active not recruitingPHASE1
A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer
This study is testing new ways to give medicines called niraparib and abiraterone acetate for men with advanced prostate cancer. Researchers want to see how well different forms of these drugs are absorbed by the body to help patients get the best treatment.
United States · Belgium · France - active not recruitingPHASE3
A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
This study looks at a new drug, apalutamide, combined with standard hormone therapy for men with high-risk prostate cancer before and after surgery. It aims to see if this combination helps shrink the cancer more and prevents it from spreading, compared to hormone therapy alone.
United States · Argentina · Australia - active not recruitingPHASE3
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
This study looks at a new treatment called 177Lu-PSMA-617 for men with advanced prostate cancer that has spread. It compares this new treatment alongside standard care to standard care alone, aiming to see if it helps patients live longer without their cancer getting worse.
United States · Austria · Belgium - recruitingPHASE2
Dose Escalation For INtraprostatic LEsions
This study explores a new way to give radiotherapy for prostate cancer. It uses powerful scans to target the cancer more precisely and delivers treatment in fewer, stronger doses. The aim is to see if this method is safe and works better than current treatments.
Canada - active not recruiting
PSMA PET/CT for Assessment of Recurrent Prostate Cancer
This study uses a special scan called PSMA PET/CT to find prostate cancer that has returned. It helps doctors see where the cancer is more clearly, especially when other scans aren't sure. This can help guide treatment decisions.
Canada - recruitingPHASE1
A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer
This study looks at new drug combinations for advanced prostate cancer. Researchers want to find the safest and most effective doses of new medicines and see how well they work together, sometimes with existing treatments, to help men with this type of cancer.
United States · France · Japan - active not recruitingNA
Molecular Mechanisms of Dutasteride and Dietary Interventions to Prevent Prostate Cancer and Reduce Its Progression
This study looks at whether a special diet rich in omega-3 or a drug called dutasteride can stop low-risk prostate cancer from getting worse. It involves diet changes and medication over a year to see what works best.
Canada - active not recruitingPHASE3
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
This study is looking at whether adding a drug called apalutamide to standard prostate cancer treatments (radiotherapy and hormone therapy) helps men with high-risk prostate cancer live longer without their cancer spreading. It compares the new combination to the standard treatment alone.
United States · Australia · Austria - recruiting
A Study to Assess Adherence to Apalutamide in Metastatic Hormone-Sensitive Prostate Cancer Participants in France
This study looks at how well men with a certain type of prostate cancer (metastatic hormone-sensitive prostate cancer) stick to their apalutamide medication in France. It wants to understand why some men might not take their medicine as prescribed.
France - recruitingPHASE1, PHASE2
Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
This study is testing a new treatment for advanced prostate cancer that has spread and isn't responding to usual hormone therapy. It's called 177Lu-rhPSMA-10.1 and uses radiation to target cancer cells. We want to see how safe and effective it is.
United States · Belgium · Germany